Market Place
Sourcing Support
Catalyst Pharma to Participate in Upcoming Investor Conferences
19 Nov 2024 //
GLOBENEWSWIRE
Catalyst Pharma Recognized Among BioSpace 2025 Best Places to Work
13 Nov 2024 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals Reports Strong Q3 2024 Financials
06 Nov 2024 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals To Report Q3 2024 Results On Nov 6
22 Oct 2024 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals Donates $100,000 For Hurricane Relief
08 Oct 2024 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals Joins BofA Securities CNS Conference
01 Oct 2024 //
GLOBENEWSWIRE
Catalyst’s Sub-Licensee DyDo Gets Approval for FIRDAPSE in Japan
24 Sep 2024 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
20 Aug 2024 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals Reports Strong Q2 2024 Results And Updates
07 Aug 2024 //
GLOBENEWSWIRE
Catalyst Pharma Licenses AGAMREE To Kye Pharma For Canada Market
24 Jul 2024 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals To Report Q2 2024 Results On August 7, 2024
22 Jul 2024 //
GLOBENEWSWIRE
Catalyst Gets Higher FIRDAPSE® Maximum Dose Approval From FDA
31 May 2024 //
GLOBENEWSWIRE
Catalyst Pharma: Presenting At Jefferies Healthcare Conference 2024
28 May 2024 //
GLOBENEWSWIRE
Catalyst Pharma Q1 2024 Results, Business Update
08 May 2024 //
GLOBENEWSWIRE
Catalyst Pharma At BofA Healthcare Conference 2024
01 May 2024 //
GLOBENEWSWIRE
Catalyst Pharma Q1 2024 Results May 8
22 Apr 2024 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals Announces Support for the Inaugural LEMS Awareness Day
28 Mar 2024 //
GLOBENEWSWIRE
Catalyst to Participate in the 2024 Cantor Virtual MDS
27 Mar 2024 //
GLOBENEWSWIRE
Santhera™s Partner Catalyst Launches AGAMREE® (Vamorolone) in the United States
14 Mar 2024 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals Announces AGAMREE Now Commercially Available
13 Mar 2024 //
GLOBENEWSWIRE
Catalyst to Participate at the Barclays 26th Annual Global Healthcare Conference
05 Mar 2024 //
GLOBENEWSWIRE
Catalyst Reports Strong Fourth Quarter and Full Year 2023 Financial Results=
28 Feb 2024 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference
27 Feb 2024 //
GLOBENEWSWIRE
Catalyst Announces Publication of Santhera`s VISION-DMD Vamorolone Study Results
21 Feb 2024 //
GLOBENEWSWIRE
Catalyst to Report Fourth Quarter and Full-Year 2023 Financial Results
14 Feb 2024 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering
09 Jan 2024 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals Announces Pricing of Public Offering of Common Stock
05 Jan 2024 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals Announces Proposed Public Offering of Common Stock
04 Jan 2024 //
GLOBENEWSWIRE
Catalyst Announces FIRDAPSE NDA Submitted in Japan by Partner DyDo Pharma
18 Dec 2023 //
GLOBENEWSWIRE
Catalyst Receives Ranking on Forbes List of America
05 Dec 2023 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as CFO
04 Dec 2023 //
GLOBENEWSWIRE
Catalyst To Participate in Piper Sandler 35th Annual Healthcare Conference
16 Nov 2023 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
02 Nov 2023 //
GLOBENEWSWIRE
Catalyst Pharma Partners with Sofie`s Journey to Bring Focus on Epilepsy
30 Oct 2023 //
GLOBENEWSWIRE
Catalyst to Report Third Quarter 2023 Financial Results on November 8, 2023
23 Oct 2023 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
19 Oct 2023 //
GLOBENEWSWIRE
Patrick J. McEnany, Chairman and CEO of Catalyst Receives Prestigious 2023 Award
16 Oct 2023 //
GLOBENEWSWIRE
Catalyst Announces FDA Acceptance of the Supplemental NDA for FIRDAPSE®
13 Oct 2023 //
GLOBENEWSWIRE
Catalyst to Participate at the 2023 Cantor Global Healthcare Conference
18 Sep 2023 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals Announces Abstract on LEMS to be Presented at the IASLC
16 Aug 2023 //
GLOBENEWSWIRE
Catalyst Announces Multiple Abstracts on FYCOMPA from Eisai to be Presented
14 Aug 2023 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst by Year-End
25 Jul 2023 //
GLOBENEWSWIRE
Catalyst to Report Second Quarter 2023 Financial Results on August 9, 2023
24 Jul 2023 //
GLOBENEWSWIRE
Catalyst Pharma Acquires Exclusive North American License For Vamorolone
19 Jul 2023 //
GLOBENEWSWIRE
Santhera Announces Closing of Agreement with Catalyst for Vamorolone
19 Jul 2023 //
GLOBENEWSWIRE
Catalyst to License North American Rights to Vamorolone for DMD from Santhera
20 Jun 2023 //
GLOBENEWSWIRE
Santhera and Catalyst Pharmaceuticals sign $231m license and collaboration deal
20 Jun 2023 //
PHARMAFILE
Santhera Grants Exclusive North America License for Vamorolone to Catalyst
20 Jun 2023 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023
01 Jun 2023 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors
30 May 2023 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals Reports Record 1Q 2023 Results
10 May 2023 //
GLOBENEWSWIRE
Catalyst Pharma Advances sNDA Submission Plans To Increase Dose For FIRDAPSE
09 May 2023 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report
01 May 2023 //
GLOBENEWSWIRE
Catalyst Pharmaceuticals to Report 1Q 2023 FYR on May 10, 2023
24 Apr 2023 //
GLOBENEWSWIRE
Catalyst Announces Third-Party Abstracts on FYCOMPA® (Perampanel)
20 Apr 2023 //
GLOBENEWSWIRE
Catalyst Pharma Reports Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 //
GLOBENEWSWIRE
Catalyst Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results
01 Mar 2023 //
GLOBENEWSWIRE
Catalyst to Ring Nasdaq Closing Bell in Honor of International Rare Disease Day
22 Feb 2023 //
GLOBENEWSWIRE
